Kalaris Therapeutics Inc (KLRS) investor relations documents from the company's IR site: 3 presentations, 12 press releases; latest deck 2026-08-01. Read in-app with summaries. First-party data.
Corporate Presentation - August 2026: Kalaris is a clinical-stage biopharma developing TH103, a next-generation anti-VEGF fusion protein for retinal diseases, with Phase 1b/2 data expected in 1H 2027.
KLRS overview · KLRS earnings · KLRS financials · KLRS KPIs · KLRS ownership · KLRS peers · KLRS filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.